Notch pathway as candidate therapeutic target in Her2/Neu/ErbB2 receptor-negative breast tumors

Oncology Reports

Volumn 23, Issue 1, 2010, Pages 35-43

  Hirose, Hajime ^a   Ishii, Hideshi ^a,b   Mimori, Koshi ^b   Ohta, Daisuke ^b   Ohkuma, Masahisa ^a   Tsujii, Hirohiko ^c   Saito, Toshiyuki ^c   Sekimoto, Mitsugu ^a   Doki, Yuichiro ^a   Mori, Masaki ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

Breast tumors; ErbB2 receptor; Notch

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; NOTCH1 RECEPTOR; NOTCH3 RECEPTOR;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CELL SURVIVAL; CLINICAL ARTICLE; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADULT; AGED; ANTIGENS, CD44; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MODELS, BIOLOGICAL; RECEPTOR, ERBB-2; RECEPTORS, NOTCH; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 76049096035     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000603     Document Type: Article

References (50)

1. Montgomery DA, Krupa K and Cooke TG: Follow-up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature. Br J Cancer: 97: 1632-1641, 2007.
2. Coleman MP, Rachet B, Woods LM, et al: Trends and socio-economic inequalities in cancer survival in England and Wales up to 2001. Br J Cancer 90: 1367-1373, 2004.
3. Karamouzis MV, Konstantinopoulos PA and Papavassiliou AG: Trastuzumab - mechanism of action and use. N Engl J Med 357: 1664-1666, 2007.
4. Bange J, Zwick E and Ullrich A: Molecular targets for breast cancer therapy and prevention. Nature Med 7: 548-552, 2001.
5. Menard S, Pupa SM, Campiglio M and Tagliabue E: Biologic and therapeutic role of HER2 in cancer. Oncogene 22: 6570-6578, 2003.
6. Kute T, Lack CM, Willingham M, et al: Development of Herceptin resistance in breast cancer cells. Cytometry A 57: 86-93, 2004.
7. Tan AR and Swain SM: Ongoing adjuvant trials with trastuzumab in breast cancer. Semin Oncol 30 (Suppl 16): 54-64, 2002.
8. Bray S: Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 7: 678-689, 2006.
9. Artavanis-Tsakonas S, Rand MD and Lake RJ: Notch signaling: Cell fate control and signal integration in development. Science 284: 770-776, 1999.
10. Miele L, Golde T and Osborne B: Notch signaling in cancer. Curr Mol Med 6: 905-918, 2006.
11. Shi W and Harris AL: Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials. J Mammary Gland Biol Neoplasia 11: 41-52, 2006.
12. Efstratiadis A, Szabolcs M and Klinakis A: Notch, Myc and breast cancer. Cell Cycle 6: 418-429, 2007.
13. Hu C, Dievart A, Lupien M, Calvo E, Tremblay G and Jolicoeur P: Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors. Am J Pathol 168: 973-990, 2006.
14. Corsini C, Mancuso P, Paul S, Burlini A, Martinelli G, Pruneri G and Bertolini F: Stroma cells: a novel target of herceptin activity. Clin Cancer Res 9: 1820-1825, 2003.
15. Chrestensen CA, Shuman JK, Eschenroeder A, Worthington M and Gram H: MNK1 and MNK2 regulation in HER2-overexpressing breast cancer lines. J Biol Chem 282: 4243-4252, 2007.
16. Dontu G, Liu S and Wicha MS: Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev 1: 207-213, 2005.
17. Ponti D, Zaffaroni N, Capelli C and Daidone MG: Breast cancer stem cells: an overview. Eur J Cancer 42: 1219-1224, 2006.
18. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003.
19. - breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8: R59, 2006.
20. Lapidot T, Sirard C, Vormoor J, et al: A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 367: 645-648, 1994.
21. Bonnet D and Dick JE: Human acute leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737, 1997.
22. Wulf GG, Wang RY, Kuehnle I, et al: A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98: 1166-1173, 2001.
23. Prince ME, Sivanandan R, Kaczorowski A, et al: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104: 973-978, 2007.
24. Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF and Mori M: Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cell 24: 506-513, 2006.
25. O'Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110, 2007.
26. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C and De Maria R: Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115, 2007.
27. Bao S, Wu Q, McLendon RE, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760, 2006.
28. Piccirillo SG, Reynolds BA, Zanetti N, et al: Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444: 761-765, 2006.
29. Tan BT, Park CY, Ailles LE and Weissman IL: The cancer stem cell hypothesis: a work in progress. Lab Invest 86: 1203-1207, 2006.
30. + breast cancer-initiating cells to radiation. J Natl Cancer Inst 98: 1777-1785, 2006.
31. Gotte M and Yip GW: Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 66: 10233-10237, 2006.
32. Anderson LM and Gibbons GH: Notch: a mastermind of vascular morphogenesis. J Clin Invest 117: 299-302, 2007.
33. Domenga V, Fardoux P, Lacombe P, et al: Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev 18: 2730-2735, 2004.
34. Conlon RA, Reaume AG and Rossant J: Notch1 is required for the coordinate segmentation of somites. Development 121: 1533-1545, 1995.
35. Huppert SS, Ilagan MX, De Strooper B and Kopan R: Analysis of Notch function in presomitic mesoderm suggests a gammasecretase-independent role for presenilins in somite differentiation. Dev Cell 8: 677-688, 2005.
36. Lou H and Dean M: Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 26: 1357-1360, 2007.
37. Hambardzumyan D, Squatrito M and Holland EC: Radiation resistance and stem-like cells in brain tumors. Cancer Cell 10: 454-456, 2006.
38. Lin Q, Donahue SL and Ruley HE: Genome maintenance and mutagenesis in embryonic stem cells. Cell Cycle 5: 2710-2714, 2006.
39. Ottey M, Han SY, Druck T, et al: Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant. Br J Cancer 91: 1669-1677, 2004.
40. Hu B, Han SY, Wang X, et al: Involvement of the Fhit gene in the ionizing radiation-activated ATR/CHK1 pathway. J Cell Physiol 202: 518-523, 2005.
41. Hu B, Wang H, Wang X, et al: Fhit and CHK1 have opposing effects on homologous recombination repair. Cancer Res 65: 8613-8616, 2005.
42. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502, 2006.
43. Bailey JM, Singh PK and Hollingsworth MA: Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins. J Cell Biochem 102: 829-839, 2007.
44. Fidler I: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458, 2003.
45. Mani SA, Yang J, Brooks M, et al: Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA 104: 10069-10074, 2007.
46. Tommiska J, Bartkova J, Heinonen M, et al: The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene 27: 2501-2506, 2008.
47. Reedijk M, Odorcic S, Chang L, et al: High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65: 8530-8537, 2005.
48. Florena AM, Tripodo C, Guarnotta C, et al: Associations between Notch-2, Akt-1 and HER2/neu expression in invasive human breast cancer: a tissue microarray immunophenotypic analysis on 98 patients. Pathobiology 74: 317-322, 2007.
49. Dickson BC, Mulligan AM, Zhang H, Lockwood G, O'Malley FP, Egan SE and Reedijk M: High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol 20: 685-693, 2007.
50. Reedijk M, Pinnaduwage D, Dickson BC, et al: JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Res Treat 111: 439-448, 2008.